Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial CancerPR Newswire•30/07/2026•16:05 ET0 ShareWhiz InsightsGenerateGet startedCreate a free account to read the full story.Sign UpAlready have an account? Log inForgot password?
